Back to Search
Start Over
Immunosuppression therapy is effective for both acquired tumor-associated and primary pure red cell aplasia: a match pair case-control study
- Source :
- Annals of Hematology. 99:1485-1491
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- No agreement had been reached on the treatment of patients with pure red cell aplasia (PRCA) secondary to indolent malignancies. Data was collected from patients with acquired PRCA from May, 2014 to May, 2018 in Peking Union Medical College Hospital. Tumor-associated PRCA and primary PRCA patients were matched at a ratio of 1:2 with compatible baseline characteristics. All patients had been treated with CsA or sirolimus for at least 6 months with the efficacy and adverse events recorded. Twelve tumor-associated PRCA patients (3 thymoma, 8 lymphoproliferative disorders, and 1 smoldering multiple myeloma) with stable underling disease and 24 acquired primary PRCA patients were selected. 83.3% tumor-associated PRCA patients and 100% primary PRCA patients (P = 0.436) responded to immunosuppression therapy (IST) at a median of 2.5 and 3.5 months (P = 0.137), respectively. No different was found in side effects. The ORR at the end of a median of 21.5-month follow-up was 75% and 70.8% (P = 0.795), respectively. No tumor progression was reported except one secondary patient had lymphoma relapse after 2 years of IST and was given chemotherapy again. These results suggested IST had similar effect, safety on patients with tumor-associated, and primary PRCA patients when the tumors were stable.
- Subjects :
- Adult
Male
medicine.medical_specialty
Thymoma
Lymphoma
Matched-Pair Analysis
medicine.medical_treatment
Pure red cell aplasia
Lymphoproliferative disorders
Red-Cell Aplasia, Pure
urologic and male genital diseases
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Neoplasms
Internal medicine
Humans
Medicine
Multiple myeloma
Aged
Immunosuppression Therapy
Chemotherapy
Hematology
business.industry
Immunosuppression
Thymus Neoplasms
General Medicine
Middle Aged
medicine.disease
Lymphoproliferative Disorders
Treatment Outcome
Case-Control Studies
030220 oncology & carcinogenesis
Female
business
Immunosuppressive Agents
030215 immunology
Subjects
Details
- ISSN :
- 14320584 and 09395555
- Volume :
- 99
- Database :
- OpenAIRE
- Journal :
- Annals of Hematology
- Accession number :
- edsair.doi.dedup.....9aaf5ba8f1a2f731f7775ec88852d729